Record performance was driven by a fully delegated care model that prioritizes clinical execution and physician alignment over coding intensity or arbitrage.

Revenue growth of 43% in Q4 and 56% for the full year reflects successful geographic diversification, with non-California revenue now representing approximately 19% of the total.

Medical cost trends remained well-controlled at approximately 4.5% for legacy operations, attributed to high patient engagement and an 80% completion rate for annual wellness visits.

The proprietary technology platform drove significant operating leverage, reducing adjusted G&A as a percentage of revenue by 110 basis points year over year.

Management maintains a disciplined approach to risk, only entering full-risk arrangements when rates align with medical cost trends and data infrastructure is mature.

The Prospect Health integration is ahead of schedule, with 97% primary care physician retention and expectations to hit the high end of the $12 million to $15 million synergy target.

2026 guidance assumes a conservative medical cost trend of just over 5%, accounting for potential adverse selection from Medicaid and exchange disenrollments.

Approximately 80% of revenue and 36% of owned membership are expected to transition to full-risk arrangements by the end of Q1 2026.

The 2026 framework embeds a 10% to 15% decline in Medicaid enrollment and zero contribution from the California Hospital Quality Assurance Fund as a matter of prudence.

Management anticipates the 2027 Medicare Advantage Advance Rate Notice will be more favorable for Astrana than the industry average due to a lack of reliance on audio-only visits or unlinked charts.

Future EBITDA expansion is expected to be fueled by AI-driven automation in prior authorizations, claims adjudication, and real-time provider workflows.

A material weakness in internal controls over financial reporting was identified related to acquisition accounting processes, though no material misstatements occurred.

The company increased its stock repurchase program from $50 million to $100 million, reflecting confidence in long-term value and a disciplined capital allocation strategy.

One-time transaction costs of $26 million were incurred in 2025, primarily related to the Prospect Health acquisition and integration efforts.

Management flagged a potential 1% to 1.5% negative spread on Medicaid rate-acuity mismatch as a specific headwind for the 2026 fiscal year.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management is modeling a conservative 5% blended trend, with Medicare Advantage expected to be lower and Medicaid/Exchange slightly higher.

The increase from 2025's 4.5% trend is a precautionary buffer against potential adverse selection during redetermination cycles.

The $265 million midpoint is supported by mid-$20 million from contract rate conversions and high-single-digit millions from Prospect synergies.

These tailwinds are partially offset by a projected $20 million negative impact from Medicaid disenrollment and rate-acuity mismatch, alongside a separate mid-single-digit impact from the exclusion of the California Hospital Quality Assurance Fund.

Astrana expects a 2.5% to 3% positive rate impact because their encounter-based model does not rely on the diagnosis sources CMS is currently targeting for disallowance.

Management remains confident in the 2027 EBITDA target of $350 million, though they noted the environment has evolved since that goal was set.

AI tools currently automate over two-thirds of prior authorizations and are being expanded to handle claims adjudication and fraud detection.

The technology is designed to lower total cost of care and reduce G&A rather than being used to maximize reimbursement through coding.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.